PharmiWeb.com - Global Pharma News & Resources
14-Feb-2019

Anti-Obesity Prescription Drugs Market: In-Depth Study of Production Demand and Consumption Growth Ratio by 2028

Obesity is a medical condition in which excess body fat get saturated into human body to the level that it may have adverse impact on health. Obesity results from a combination of causes and individual factors such as behavior and genetics. Behaviors can include dietary patterns, limited physical activity, medication use, and other exposures. Body Mass Index (BMI) is a method used for measuring obesity among people.

The report offers in-depth insights, revenue details, and other vital information regarding the global anti-obesity prescription drugs market, and the various trends, drivers, restraints, opportunities, and threats in the target market till 2027.

Increased uptake of food products with high level of cholesterol leads to obesity which in turn is expected to drive the consumption of anti-obesity drug. Limited physical activities and hereditary diseases are some of the other factors driving the demand of anti-obesity prescription drug market. Changing lifestyle patterns, sharp growth in package food consumption of diabetic and psychotropic drugs are some other factors that are expected to drive the growth of global anti-obesity prescription drug market.

High cost involved in research and development and manufacturing process of anti-obesity prescription drugs, growing number of herbal weight loss products, side effects of anti-obesity drugs, and rising acceptances of alternative options such as gymnasiums, fitness spas and therapies are expected to inhibit the growth of anti-obesity prescription drug market. Some of the other factors include; increasing patient compliance for surgical procedures, high change in diet plan are the factors that are expected to hamper the demand of anti-obesity drug market. In addition to rise in organic and fat-free products are expected to hinder the growth of anti-prescription drug market to a certain extent.

The global anti-obesity prescription drug market report has been segmented on the basis of mechanism of action, target site, therapy, distribution channel and region. On the basis of region, the global anti-obesity prescription drug market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.

Global anti-obesity prescription drugs market segmentation by mechanism of action:

  • Incretin mimetics/GLP-1 agonists
  • SNDRIs
  • Lipase inhibitors
  • Serotonin receptor agonists
  • Sympathomimetic-GABA receptor agonists
  • Sympathomimetics
  • Others (human Glucagon-like peptide-1 analog, inhibitors of dopamine & noradrenalin etc.)

Global anti-obesity prescription drugs market segmentation by target site:

  • Peripherally acting anti-obesity drugs
  • Centrally acting anti-obesity drugs

Global anti-obesity prescription drugs market segmentation, by therapy:

  • Monotherapies
  • Polytherapies

Global anti-obesity prescription drugs market segmentation, by distribution channel:

  • Hospital
  • Clinics
  • Pharmacies

Get Free Sample Copy Of This Research @ https://marketresearch.biz/report/anti-obesity-prescription-drugs-market/request-sample/

New drug delivery method of skin patch that allows anti-obesity drugs to be administered with a lowing threat of side effects, nano sized soy phytosome-based thermogel as topical anti-obesity formulation, Herbal supplements, Gene mutation related to obesity is the new treatment trend in anti-obesity drug market.

Key market players in the global anti-obesity market are Bristol-Myers Squibb Co., Takeda Pharmaceutical Company Ltd., Eisai Co., Ltd., GlaxoSmithKline plc, Pfizer Inc., Shionogi USA, Inc., Vivus Inc., Zafgen Inc., Norgine BV and, Boehringer Ingelheim GmbH.

Editor Details

Last Updated: 14-Feb-2019